These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31754924)

  • 41. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
    Trotter CL; Edmunds WJ
    Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact.
    Christensen H; Hickman M; Edmunds WJ; Trotter CL
    Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy, safety, and cost-effectiveness of meningococcal vaccines].
    Chinese Preventive Medicine Association
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):129-135. PubMed ID: 30744260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of alternative strategies for vaccination of adolescents against serogroup B IMD with the MenB-FHbp vaccine in Canada.
    Breton MC; Huang L; Snedecor SJ; Cornelio N; Fanton-Aita F
    Can J Public Health; 2020 Apr; 111(2):182-192. PubMed ID: 31907760
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
    Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ
    Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluating the Impact of Meningococcal Vaccines With Synthetic Controls.
    Prunas O; Weinberger DM; Medini D; Tizzoni M; Argante L
    Am J Epidemiol; 2022 Mar; 191(4):724-734. PubMed ID: 34753175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meningococcal infections among refugees and immigrants: silent threats of past, present and future.
    Dinleyici EC; Borrow R
    Hum Vaccin Immunother; 2020 Nov; 16(11):2781-2786. PubMed ID: 32347773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.
    Parikh SR; Campbell H; Bettinger JA; Harrison LH; Marshall HS; Martinon-Torres F; Safadi MA; Shao Z; Zhu B; von Gottberg A; Borrow R; Ramsay ME; Ladhani SN
    J Infect; 2020 Oct; 81(4):483-498. PubMed ID: 32504737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease.
    Taha MK; Martinon-Torres F; Köllges R; Bonanni P; Safadi MAP; Booy R; Smith V; Garcia S; Bekkat-Berkani R; Abitbol V
    Expert Rev Vaccines; 2022 May; 21(5):659-674. PubMed ID: 35271781
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluating Vaccination Programs That Prevent Diseases With Potentially Catastrophic Health Outcomes: How Can We Capture the Value of Risk Reduction?
    Mauskopf J; Masaquel C; Huang L
    Value Health; 2021 Jan; 24(1):86-90. PubMed ID: 33431158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meningococcal vaccination for adolescents? An economic evaluation in Victoria.
    Skull SA; Butler JR
    J Paediatr Child Health; 2001 Oct; 37(5):S28-33. PubMed ID: 11885733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease.
    Marten O; Koerber F; Bloom D; Bullinger M; Buysse C; Christensen H; De Wals P; Dohna-Schwake C; Henneke P; Kirchner M; Knuf M; Lawrenz B; Monteiro AL; Sevilla JP; Van de Velde N; Welte R; Wright C; Greiner W
    Health Qual Life Outcomes; 2019 May; 17(1):87. PubMed ID: 31118091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme.
    Moura Silveira M; McBride AJA; Trotter CL
    Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.
    Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L
    BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations.
    Acevedo R; Bai X; Borrow R; Caugant DA; Carlos J; Ceyhan M; Christensen H; Climent Y; De Wals P; Dinleyici EC; Echaniz-Aviles G; Hakawi A; Kamiya H; Karachaliou A; Lucidarme J; Meiring S; Mironov K; Sáfadi MAP; Shao Z; Smith V; Steffen R; Stenmark B; Taha MK; Trotter C; Vázquez JA; Zhu B
    Expert Rev Vaccines; 2019 Jan; 18(1):15-30. PubMed ID: 30526162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands.
    Bos JM; Rümke H; Welte R; Postma MJ
    Clin Ther; 2003 Oct; 25(10):2614-30. PubMed ID: 14667962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.
    Rozenbaum MH; Sanders EA; van Hoek AJ; Jansen AG; van der Ende A; van den Dobbelsteen G; Rodenburg GD; Hak E; Postma MJ
    BMJ; 2010 Jun; 340():c2509. PubMed ID: 20519267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.